171 related articles for article (PubMed ID: 16154561)
1. The role of 5-HT(2A) receptor antagonism in amphetamine-induced inhibition of A10 dopamine neurons in vitro.
Olijslagers JE; Perlstein B; Werkman TR; McCreary AC; Siarey R; Kruse CG; Wadman WJ
Eur J Pharmacol; 2005 Sep; 520(1-3):77-85. PubMed ID: 16154561
[TBL] [Abstract][Full Text] [Related]
2. 5-HT2 receptors differentially modulate dopamine-mediated auto-inhibition in A9 and A10 midbrain areas of the rat.
Olijslagers JE; Werkman TR; McCreary AC; Siarey R; Kruse CG; Wadman WJ
Neuropharmacology; 2004 Mar; 46(4):504-10. PubMed ID: 14975674
[TBL] [Abstract][Full Text] [Related]
3. Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells.
Stockton ME; Rasmussen K
Psychopharmacology (Berl); 1996 Mar; 124(1-2):50-6. PubMed ID: 8935800
[TBL] [Abstract][Full Text] [Related]
4. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K
Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
[TBL] [Abstract][Full Text] [Related]
5. Effects of selective dopamine D4 receptor blockers, NRA0160 and L-745,870, on A9 and A10 dopamine neurons in rats.
Kawashima N; Okuyama S; Omura T; Chaki S; Tomisawa K
Life Sci; 1999; 65(24):2561-71. PubMed ID: 10619364
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies.
Sorensen SM; Kehne JH; Fadayel GM; Humphreys TM; Ketteler HJ; Sullivan CK; Taylor VL; Schmidt CJ
J Pharmacol Exp Ther; 1993 Aug; 266(2):684-91. PubMed ID: 8102646
[TBL] [Abstract][Full Text] [Related]
7. Clozapine blocks D-amphetamine-induced excitation of dopamine neurons in the ventral tegmental area.
Shi WX; Zhang XY; Pun CL; Bunney BS
Neuropsychopharmacology; 2007 Sep; 32(9):1922-8. PubMed ID: 17299514
[TBL] [Abstract][Full Text] [Related]
8. Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors.
Maurel-Remy S; Bervoets K; Millan MJ
Eur J Pharmacol; 1995 Jul; 280(2):R9-11. PubMed ID: 7589172
[TBL] [Abstract][Full Text] [Related]
9. Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples.
Chernet E; Martin LJ; Li D; Need AB; Barth VN; Rash KS; Phebus LA
Life Sci; 2005 Dec; 78(4):340-6. PubMed ID: 16139310
[TBL] [Abstract][Full Text] [Related]
10. The orexin-1 receptor antagonist SB-334867 blocks the effects of antipsychotics on the activity of A9 and A10 dopamine neurons: implications for antipsychotic therapy.
Rasmussen K; Hsu MA; Yang Y
Neuropsychopharmacology; 2007 Apr; 32(4):786-92. PubMed ID: 17063151
[TBL] [Abstract][Full Text] [Related]
11. In vitro modulation of the firing rate of dopamine neurons in the rat substantia nigra pars compacta and the ventral tegmental area by antipsychotic drugs.
Werkman TR; Kruse CG; Nievelstein H; Long SK; Wadman WJ
Neuropharmacology; 2001 Jun; 40(7):927-36. PubMed ID: 11378163
[TBL] [Abstract][Full Text] [Related]
12. Effects of d-amphetamine and DOI (2,5-dimethoxy-4-iodoamphetamine) on timing behavior: interaction between D1 and 5-HT2A receptors.
Body S; Cheung TH; Bezzina G; Asgari K; Fone KC; Glennon JC; Bradshaw CM; Szabadi E
Psychopharmacology (Berl); 2006 Dec; 189(3):331-43. PubMed ID: 17051415
[TBL] [Abstract][Full Text] [Related]
13. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
[TBL] [Abstract][Full Text] [Related]
14. D-2 dopamine antagonist-like effects of SCH 23390 on A9 and A10 dopamine neurons.
Goldstein JM; Litwin LC; Sutton EB; Malick JB
Life Sci; 1987 Mar; 40(11):1039-44. PubMed ID: 2950291
[TBL] [Abstract][Full Text] [Related]
15. Acute and chronic administration of the selective 5-HT1A receptor antagonist WAY-405 significantly alters the activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study.
Minabe Y; Schechter L; Hashimoto K; Shirayama Y; Ashby CR
Synapse; 2003 Dec; 50(3):181-90. PubMed ID: 14515335
[TBL] [Abstract][Full Text] [Related]
16. CI-943, a potential antipsychotic agent. III. Evaluation of effects on dopamine neuronal activity.
Meltzer LT; Christoffersen CL; Heffner TG; Freeman AS; Chiodo LA
J Pharmacol Exp Ther; 1989 Oct; 251(1):123-30. PubMed ID: 2571714
[TBL] [Abstract][Full Text] [Related]
17. Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat.
Millan MJ; Brocco M; Gobert A; Joly F; Bervoets K; Rivet J; Newman-Tancredi A; Audinot V; Maurel S
Eur J Neurosci; 1999 Dec; 11(12):4419-32. PubMed ID: 10594669
[TBL] [Abstract][Full Text] [Related]
18. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.
Kehne JH; Baron BM; Carr AA; Chaney SF; Elands J; Feldman DJ; Frank RA; van Giersbergen PL; McCloskey TC; Johnson MP; McCarty DR; Poirot M; Senyah Y; Siegel BW; Widmaier C
J Pharmacol Exp Ther; 1996 May; 277(2):968-81. PubMed ID: 8627580
[TBL] [Abstract][Full Text] [Related]
19. Selective serotonin 2A receptor antagonism attenuates the effects of amphetamine on arousal and dopamine overflow in non-human primates.
Murnane KS; Andersen ML; Rice KC; Howell LL
J Sleep Res; 2013 Oct; 22(5):581-8. PubMed ID: 23879373
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of latent inhibition by two 5-HT2A receptor antagonists only when given at both pre-exposure and conditioning.
McDonald LM; Moran PM; Vythelingum GN; Joseph MH; Stephenson JD; Gray JA
Psychopharmacology (Berl); 2003 Sep; 169(3-4):321-31. PubMed ID: 14530903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
